Triple Combo CF Drug Shows Strong Benefit in Young Children
A study of 67 children aged 2 to 5 with cystic fibrosis found that switching to the triple combination vanzacaftor-tezacaftor-deutivacaftor (VTD) improved a key marker of CFTR function. Mean sweat chloride fell from 38.4 to 28.9 mmol/L after 24 weeks, with 92% of children reaching levels below the diagnostic threshold. Adverse events were mostly mild or moderate, and none of the serious events were linked to the drug.
The TIMBERLINE trial followed 67 preschoolers already using Trikafta who transitioned to the newer Alyftrek regimen. Over 24 weeks, their sweat chloride levels dropped notably, with nearly two-thirds achieving concentrations below 30 mmol/L. Side effects were generally mild or moderate, and serious events were not attributed to the medication.
Presented at the ERS Congress and published in Lancet Respiratory Medicine, the findings also showed stable pancreatic function and normal growth. Researchers noted that structural lung and pancreatic damage begins very early, even before diagnosis. This has sparked discussion about potential in utero treatment, though no regulatory framework currently supports that approach.
This research could reshape early intervention strategies for cystic fibrosis, offering families of young children a potentially more effective option to slow organ damage. If future studies confirm long-term benefits, it may shift standard care toward initiating potent modulators even earlier, possibly before birth. This could reduce lifelong disease burden and healthcare costs, though regulatory and safety hurdles must first be cleared to make such early exposure feasible.